TLSI · TriSalus Life Sciences, Inc. · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. There can be no assurances that we will be successful in any of these respects, or that we will be able to continue to obtain outside capital in the future or do so on terms that are acceptable to us.”View the 10-Q filed Aug 6, 2026
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-22 |
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
WESTMINSTER, Colo. --(BUSINESS WIRE)--Sep. 22, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid |
| 2026-08-31 |
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
WESTMINSTER, Colo. --(BUSINESS WIRE)--Aug. 31, 2026-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary |
| 2026-08-06 |
TriSalus Life Sciences Reports Second Quarter 2026 Results
Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting Conference Call and Webcast today at 4:30pm ET DENVER --(BUSINESS WIRE)--Aug. |
| 2026-07-29 |
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
WESTMINSTER, Colo. --(BUSINESS WIRE)--Jul. 29, 2026-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary |
| 2026-07-16 |
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
WESTMINSTER, Colo. --(BUSINESS WIRE)--Jul. 16, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, |
| 2026-06-10 |
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share clinical experience and patient case examples WESTMINSTER, Colo. --(BUSINESS WIRE)--Jun. |
| 2026-05-12 |
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader market penetration Published landmark, real-world PEDD ® Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure |
| 2026-05-12 |
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance despite greater baseline clinical complexity WESTMINSTER, Colo. |
| 2026-05-04 |
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
WESTMINSTER, Colo. --(BUSINESS WIRE)--May 4, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid |
| 2026-04-28 |
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
Conference Call and Webcast Scheduled for Tuesday, May 12, 2026 at 4:30 PM WESTMINSTER, Colo. --(BUSINESS WIRE)--Apr. 28, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its |
| 2026-04-09 |
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
WESTMINSTER, Colo. --(BUSINESS WIRE)--Apr. 9, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid |